Geller Advisors LLC Has $1.06 Million Stock Holdings in Abbott Laboratories (NYSE:ABT)

Geller Advisors LLC trimmed its position in shares of Abbott Laboratories (NYSE:ABT) by 1.8% in the 4th quarter, Holdings Channel.com reports. The fund owned 9,384 shares of the healthcare product maker’s stock after selling 168 shares during the quarter. Geller Advisors LLC’s holdings in Abbott Laboratories were worth $1,061,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Greenline Partners LLC purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth about $149,000. Ground Swell Capital LLC acquired a new position in Abbott Laboratories in the fourth quarter worth approximately $231,000. Full Sail Capital LLC raised its position in Abbott Laboratories by 2.7% during the fourth quarter. Full Sail Capital LLC now owns 4,022 shares of the healthcare product maker’s stock valued at $455,000 after acquiring an additional 105 shares in the last quarter. Elefante Mark B acquired a new stake in Abbott Laboratories in the fourth quarter valued at approximately $3,706,000. Finally, Ethic Inc. grew its position in Abbott Laboratories by 12.5% in the fourth quarter. Ethic Inc. now owns 188,276 shares of the healthcare product maker’s stock worth $21,296,000 after acquiring an additional 20,879 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Down 0.4 %

ABT stock opened at $133.50 on Friday. The business’s 50-day simple moving average is $129.80 and its 200 day simple moving average is $123.46. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. The company has a market cap of $232.27 billion, a PE ratio of 17.45, a price-to-earnings-growth ratio of 2.52 and a beta of 0.74. Abbott Laboratories has a twelve month low of $99.71 and a twelve month high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.02. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.38 billion. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. On average, research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be paid a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.77%. The ex-dividend date of this dividend is Tuesday, April 15th. Abbott Laboratories’s dividend payout ratio is 30.61%.

Insider Transactions at Abbott Laboratories

In related news, Director Sally E. Blount sold 2,600 shares of the firm’s stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total transaction of $337,116.00. Following the completion of the transaction, the director now owns 34,058 shares in the company, valued at $4,415,960.28. This trade represents a 7.09 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Eric Shroff sold 562 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total value of $77,651.54. Following the completion of the sale, the senior vice president now owns 31,970 shares in the company, valued at $4,417,294.90. This trade represents a 1.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 95,278 shares of company stock valued at $12,745,859. Company insiders own 0.46% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ABT. The Goldman Sachs Group upped their price objective on shares of Abbott Laboratories from $138.00 to $154.00 and gave the stock a “buy” rating in a report on Tuesday, March 4th. Wells Fargo & Company upped their price target on Abbott Laboratories from $136.00 to $147.00 and gave the stock an “overweight” rating in a research note on Thursday, April 17th. StockNews.com lowered Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 12th. Argus upgraded Abbott Laboratories to a “strong-buy” rating in a report on Tuesday, January 28th. Finally, Bank of America boosted their price objective on shares of Abbott Laboratories from $133.00 to $150.00 and gave the stock a “buy” rating in a research note on Monday, March 10th. Four research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $142.59.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.